Indications for: DHIVY
Treatment of Parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.
Individualize. Initially one tab (25mg/100mg) 3 times daily; may increase by up to one whole tab every day or every other day as needed; max 8 whole tabs daily.
During or within 14 days of nonselective MAOIs (eg, phenelzine, linezolid, tranylcypromine).
Sleep disorders; consider discontinuing if significant daytime sleepiness occurs. History of MI with residual arrhythmias; monitor cardiac function. Risk of hallucinations and psychosis. Major psychotic disorder: not recommended. Depression. Suicidal tendencies. Impulse control/compulsive behaviors; consider dose reduction or discontinuation if develops. Peptic ulcer. Glaucoma; monitor IOP. Withdrawal-emergent hyperpyrexia or confusion: avoid sudden discontinuation or rapid dose reduction. Pregnancy. Nursing mothers.
Dopa-decarboxylase inhibitor + dopamine precursor.
See Contraindications. Concomitant dopamine-depleting agents (eg, reserpine, tetrabenazine) or other drugs known to deplete monoamine stores: not recommended. Antagonized by dopamine D2 receptor antagonists (eg, phenothiazines, butyrophenones, risperidone, metoclopramide), isoniazid, iron salts. Delayed absorption with high-protein diet, high-fat, high-calorie meals or excessive acidity. May cause false (+) urinary ketone test or false (–) urinary glucose (glucose oxidase) test.
Dyskinesias (eg, choreiform, dystonic), other involuntary movements, nausea; cardiovascular ischemic events, lab abnormalities.
Generic Drug Availability: